TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24180167

Group type: COMPARATOR
Intervention: US (ultrasound guided continuous popliteal sciatic nerve block)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: US+NS (ultrasound guided continuous popliteal sciatic nerve block with nerve stimulation)
Number of subjects: 21

Group type: COMPARATOR
Intervention: US only
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: US+NS
Number of subjects: 21

Group type: COMPARATOR
Intervention: US
Number of subjects: 21
Study: 21473825

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation with synchronous intermittent mandatory ventilation and pressure support ventilation (SIMV+PSV) followed by non-invasive ventilation with PSV and PEEP after extubation.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ordinary way of weaning from mechanical ventilation.
Number of subjects: 20
Study: 18835515

Group type: EXPERIMENTAL
Intervention: Superior placement of the acetabular cup
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inferior placement of the acetabular cup
Number of subjects: 50
Study: 17345002

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 231
Study: 14687054

Group type: EXPERIMENTAL
Intervention: Six months cytological surveillance
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Choice between six months cytological surveillance or colposcopy
Number of subjects: 476

Group type: COMPARATOR
Intervention: No choice (six months cytological surveillance)
Number of subjects: 476
Study: 11485146

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study: 9215339

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison of i.v. and SC routes
Number of subjects: 6
Study: 8490373

Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment procedure by community psychogeriatric teams
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical and non‐medical team members
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Team members with longer experience of team working
Number of subjects: 100
Study: 3038428

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg tid
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 15 mg tid
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (C + H) tid
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 30177350

Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo program
Number of subjects: 91
Study: 28464975

Group type: EXPERIMENTAL
Intervention: Full treatment protocol (experimental condition)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Treatment protocol without systematic exposure (control)
Number of subjects: 309
Study: 26296554

Group type: EXPERIMENTAL
Intervention: Primary care-based intervention including population-based screening, centralized delivery of intervention components, involvement of primary care practitioners, and personalization of intervention components.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned; details on control intervention not available.
Number of subjects: 0
Study: 23512283

Group type: EXPERIMENTAL
Intervention: On-site evaluation of FNAB specimens
Number of subjects: 204

Group type: COMPARATOR
Intervention: Regular cytologic examination
Number of subjects: 204
Study: 21039358

Group type: EXPERIMENTAL
Intervention: 5.0 mg/ml bupivacaine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2.5 mg/ml bupivacaine
Number of subjects: 16
Study: 18495561

Group type: EXPERIMENTAL
Intervention: Pitavastatin (1, 2 and 4 mg)
Number of subjects: 0
Study: 17121050

Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza Injection (SMI)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SI)
Number of subjects: 79
Study: 11976818

Group type: EXPERIMENTAL
Intervention: Amifostine (AMF) 300 mg/m2, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Amifostine (AMF) 400 mg/m2, given after initial treatment in group A.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Amifostine (AMF) 400 mg/m2 in group B, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall response rate for both groups.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bone marrow progenitor assay pre- and post-amifostine treatment in group A.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clonogenic assay in group B before AMF treatment.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Predictive power of clonogenic assays for treatment response.
Number of subjects: 27
Study: 10678139

Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7549337

Group type: EXPERIMENTAL
Intervention: Mean pallor value in ocular hypertensive patients (0.40)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mean pallor value in glaucoma patients (0.50)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Mean pallor value comparison: Ocular hypertensives (0.40) vs. POAG (0.50)
Number of subjects: 33
Study: 1682905

Group type: EXPERIMENTAL
Intervention: Alfuzosin (2.5 mg b.i.d. up to 10 mg b.i.d.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propranolol (40 mg b.i.d. up to 160 mg b.i.d.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 6922456

Group type: EXPERIMENTAL
Intervention: Towel bath
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional bed bath
Number of subjects: 105
Study: 30907856

Group type: EXPERIMENTAL
Intervention: Subsidized spectacles provided to children with unmet need (n = 1191)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Subsidized spectacles provided to children with poor unaided vision
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Subsidized spectacles scheme
Number of subjects: 1191
Study: 31515436

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28505954

Group type: EXPERIMENTAL
Intervention: Manipulative rehabilitation (8 sessions, 30 minutes each, twice weekly for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Active control care
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Manipulative rehabilitation
Number of subjects: 21
Study: 26355164

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin plus trastuzumab
Number of subjects: 130

Group type: COMPARATOR
Intervention: S‐1 plus cisplatin alone
Number of subjects: 130
Study: 23187931

Group type: EXPERIMENTAL
Intervention: Local anesthesia and intravenous sedation
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 20
Study: 21606413

Group type: COMPARATOR
Intervention: Intermediate-dose cytarabine (12 g/m²)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (36 g/m²)
Number of subjects: 933
Study: 19564837

Group type: EXPERIMENTAL
Intervention: Inactivated subunit vaccine
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study: 16960527

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate-electrolyte solution (CES)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 2% dehydration (DEH)
Number of subjects: 15
Study: 15056196

Group type: EXPERIMENTAL
Intervention: Objects labeled with the same noun
Number of subjects: 123

Group type: COMPARATOR
Intervention: Objects not labeled
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Objects labeled with different nouns
Number of subjects: 123
Study: 11342725

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.5% 10 ml, 50 mg) injected into cannula sites before incisions and 10 ml diluted with 100 ml saline into the peritoneal cavity at completion of the procedure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Physiologic saline (equal amount used in controls)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 150
Study: 9146812

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 200 mg biweekly for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7962369

Group type: EXPERIMENTAL
Intervention: 10% maternal serum from smoking women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% maternal serum from non-smoking women
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% maternal serum (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10% male serum (control)
Number of subjects: 0
Study: 2890365

Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg kg‐1) without priming dose (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.09 mg kg‐1) with priming dose of 0.015 mg kg‐1 (Group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.085 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.08 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 4)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Suxamethonium (1.5 mg kg‐1) (Group 5)
Number of subjects: 50
Study: 29436761

Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg qd (G2)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: gemigliptin 25 mg bid to 50 mg qd (G1/G2)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg qd to gemigliptin 50 mg qd (S/G2)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg qd (G2/G2)
Number of subjects: 335
Study: 27220310

Group type: EXPERIMENTAL
Intervention: Revascularization + Best Medical Therapy (BMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT)
Number of subjects: 0
Study: 23447453

Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Exercise Training (HIT), n=20
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low-Intensity Aerobic Exercise Training (LIT), n=23
Number of subjects: 43
Study: 23830536

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (standard treatment only)
Number of subjects: 15
Study: 20117319

Group type: EXPERIMENTAL
Intervention: Evidence-based guidelines for diagnosis and treatment of CTS
Number of subjects: 0
Study: 18377249

Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation (MCS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Motor cortex stimulation (MCS) OFF mode
Number of subjects: 11
Study: 16482075

Group type: EXPERIMENTAL
Intervention: Cod protein meal
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Milk protein meal
Number of subjects: 17
Study: 14563967

Group type: EXPERIMENTAL
Intervention: Intrathecal urokinase infusion (ITUKI therapy)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 110
Study: 11149069

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral outpatient chronic pain management program
Number of subjects: 61
Study: 9082657

Group type: EXPERIMENTAL
Intervention: customary fat-reduced foods (D group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: products with normal fat content (K group)
Number of subjects: 70
Study: 1615478

Group type: EXPERIMENTAL
Intervention: Hemofil M
Number of subjects: 5

Group type: COMPARATOR
Intervention: Hemofil CT (control)
Number of subjects: 5
Study: 370160

Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: DA
Number of subjects: 7

Group type: COMPARATOR
Intervention: PL
Number of subjects: 7
Study: 31608799

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg bid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prasugrel 5 mg od
Number of subjects: 20
Study: 30511291

Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care (MTPC) - an 8-week program integrated into primary care.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Low-Dose Comparator (LDC) - a 60-min mindfulness introduction, referral to community and digital resources, and addition to a 6-month waitlist for MTPC.
Number of subjects: 136
Study: 28881303

Group type: EXPERIMENTAL
Intervention: Group-based parenting program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 68
Study: 26115069

Group type: EXPERIMENTAL
Intervention: Intensive lipid lowering treatment with 80 mg rosuvastatin loading followed by 40 mg daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care group (standard statin therapy according to current guidelines)
Number of subjects: 140
Study: 23551788

Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Quality assurance processes
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Periodic audit feedback
Number of subjects: 1071
Study: 22043972

Group type: EXPERIMENTAL
Intervention: Bioactive glass S53P4 (BAG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Autograft bone (AB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (BAG and AB)
Number of subjects: 29
Study: 18991182

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 167

Group type: COMPARATOR
Intervention: Sulfamethizole
Number of subjects: 167
Study: 16202192

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN) point prevalence in women
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Eating Disorder Inventory Bulimia scores
Number of subjects: 2491
Study: 15719746

Group type: EXPERIMENTAL
Intervention: Zhitiaokang capsule (ZTK) for 8 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Zhibituo tablet (Control) for 8 weeks
Number of subjects: 186
Study: 12952517

Group type: EXPERIMENTAL
Intervention: 30 minutes of stretching with a 30 Nm torque at the hip, each weekday for four weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: No stretching (control condition)
Number of subjects: 16
Study: 10459516

Group type: EXPERIMENTAL
Intervention: Hydrosalpinx group
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study: 8541097

Group type: EXPERIMENTAL
Intervention: Non-invasive, self‐measured procedure using a thermometric brassiere for 90 min each evening
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Profiles of progesterone through the cycle obtained from daily saliva sampling
Number of subjects: 91
Study: 2172371

Group type: COMPARATOR
Intervention: Dihydralazine at a dose of 4 micrograms/kg per min (Control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Perindoprilat at a dose of 1 microgram/kg per min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Perindoprilat at a dose of 2.5 micrograms/kg per min
Number of subjects: 21
Study: 422029

Group type: EXPERIMENTAL
Intervention: Diane (cyproteronazetate 2 mg, ethinyloestradiol 50 mcg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neogynon (D‐Norgestrel 0.25 mg, ethinyloestradiol 50 mcg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lyndiol (Lynestrenol 2.5 mg with ethinyloestradiol 50 mcg)
Number of subjects: 10
Study: 29461074

Group type: EXPERIMENTAL
Intervention: Short-term memory (STM) content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computational models of visual attention
Number of subjects: 0
Study: 26260780

Group type: EXPERIMENTAL
Intervention: Rumination-focused cognitive behaviour therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy
Number of subjects: 128
Study: 23648055

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Side-posture positioning (SPP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 21936344

Group type: EXPERIMENTAL
Intervention: Tianeptine (3 x 12.5 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18421047

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/m2/d)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/m2/d) in low-risk arm
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg/m2/d) in standard/high-risk arm
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Dexamethasone pharmacokinetics
Number of subjects: 214
Study: 16025957

Group type: EXPERIMENTAL
Intervention: Danning Tablet (DNT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 135
Study: 12660056

Group type: EXPERIMENTAL
Intervention: Stepped care (3-month multicomponent intervention led by a non-medical health worker including psychoeducational group intervention, structured follow-up, and drug treatment for severe depression)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 11512206

Group type: EXPERIMENTAL
Intervention: Culturally competent AIDS education program (specialized program)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Culturally competent AIDS education program (traditional program)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Both AIDS education programs
Number of subjects: 410
Study: 8551753

Group type: EXPERIMENTAL
Intervention: Heparin-coated perfusion circuits (Carmeda process; Medtronic Cardiopulmonary)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard systemic heparin (300 U/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits
Number of subjects: 20
Study: 1867303

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 1% suspension
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 1% suspension (after placebo)
Number of subjects: 50
Study: 7068283

Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg administered thrice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amoxycillin administered thrice daily
Number of subjects: 50
Study: 30191395

Group type: EXPERIMENTAL
Intervention: Behavioural therapy with a written checklist for parents to fully complete (Group II)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Behavioural therapy as a written guideline (Group I)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Desmopressin treatment plus verbal behavioural therapy (Group III)
Number of subjects: 79
Study: 27714892

Group type: EXPERIMENTAL
Intervention: Partners in Health scale for older adults (PIH-OA)
Number of subjects: 1127
Study: 26467797

Group type: EXPERIMENTAL
Intervention: Modified Glasgow prognostic score = 2
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Preoperative CA19‐9 ≥300 U/ml
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Tumor size ≥30 mm
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: 0, 1 and ≥2 risk factors in R-PDAC patients
Number of subjects: 968
Study: 24124036

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention (SB-I)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (PA-I)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Combined PA+SB intervention
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study: 22946861

Group type: EXPERIMENTAL
Intervention: Simultaneous thermoradiotherapy with hyperthermia
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control sectors (unheated)
Number of subjects: 57
Study: 18555556

Group type: EXPERIMENTAL
Intervention: High-dose epirubicin/cisplatin
Number of subjects: 64
Study: 17697201

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg q.d.s.
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d.
Number of subjects: 1541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 or 80 mg)
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 1541
Study: 15161458

Group type: EXPERIMENTAL
Intervention: Maximal lower-body muscle power assessed using vertical jump height (VJH)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High thigh muscle density
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Relative area occupied by the fastest muscle fiber types (IIax+IIx)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Maximal isometric knee extension strength (KES)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low body fat mass
Number of subjects: 78
Study: 11201904

Group type: EXPERIMENTAL
Intervention: Community behaviour towards persons affected by leprosy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fear of infection and fear of a curse from God
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Leprosy control programmes
Number of subjects: 100
Study: 9380806

Group type: EXPERIMENTAL
Intervention: Maintenance Hemodialysis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (Healthy Age-Matched Subjects)
Number of subjects: 31
Study: 8328192

Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg in 90 min)
Number of subjects: 421

Group type: COMPARATOR
Intervention: APSAC
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: r-PA (10 MU)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: r-PA (15 MU)
Number of subjects: 421
Study: 3524225

Group type: EXPERIMENTAL
Intervention: Nafcillin for two weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nafcillin for four weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nafcillin for six weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nafcillin for four or six weeks
Number of subjects: 84
Study: 30646133

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, physical activity, behavior modification)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Placebo (standard information about diet and exercise)
Number of subjects: 957